干旱区生态环境知识资源中心(Arid): LC-MS/MS assay for the determination of tat-K13, a novel interfering peptide for the treatment of ischemic stroke, in human plasma and its application to a pharmacokinetics study

Arid

DOI	10.1002/bmc.5095
	LC-MS/MS assay for the determination of tat-K13, a novel interfering peptide for the treatment of ischemic stroke, in human plasma and its application to a pharmacokinetics study
	Wang, Zhenlei; Jia, Shiling; Zhang, Quan; Wang, Yongsheng; Huang, Biao; Zheng, Li
通讯作者	Zheng, L (corresponding author), Sichuan Univ, West China Hosp, GCP Ctr, Inst Drug Clin Trials, Chengdu 610041, Peoples R China. ; Huang, B (corresponding author), Covance Pharmaceut Res & Dev Co Ltd, Shanghai 200000, Peoples R China.
来源期刊	BIOMEDICAL CHROMATOGRAPHY
ISSN	0269-3879
EISSN	1099-0801
出版年	2021
卷号	35 期号:7
英文摘要	A sensitive and robust method has been developed using an ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) assay to quantify Tat-K13, a novel interfering peptide for the treatment of ischemic stroke, in human plasma. Automated solid-phase extraction on a Waters Oasis WCX (30 mu m, 10 mg) 96-well plate was used to extract Tat-K13 from human plasma and the extracts were separated on a Waters Acquity CSH column (2.1 x 50 mm i.d., 1.7 mu m) with a gradient elution method by mobile phase A (nonafluoropentanoic acid-acetic acid-water, 1:2:1000, v/v/v) and B (nonafluoropentanoic acid-acetic acid-water-acetonitrile, 1:2:100:900, v/v/v/v). The method was fully validated following international bioanalytical guidelines and showed good linearity from 2.10 to 1,050 ng/ml. The method was successfully applied to investigate the clinical pharmacokinetics of Tat-K13 in health volunteers. Rapid elimination of Tat-K13 from the body was observed, with half-life ranging from 0.26 to 0.78 h across different dose levels. The exposure of Tat-K13 was approximately dose-dependent in terms of the area under the concentration-time curve and peak concentration
英文关键词	first-in-human pharmacokinetics stroke tat-K13 UPLC-MS/MS
类型	Article
语种	英语
收录类别	SCI-E
WOS记录号	WOS:000624331000001
WOS类目	Biochemical Research Methods ; Biochemistry & Molecular Biology ; Chemistry, Analytical ; Pharmacology & Pharmacy
WOS研究方向	Biochemistry & Molecular Biology ; Chemistry ; Pharmacology & Pharmacy
资源类型	期刊论文
条目标识符	http://119.78.100.177/qdio/handle/2XILL650/349715
作者单位	[Wang, Zhenlei; Wang, Yongsheng; Zheng, Li] Sichuan Univ, West China Hosp, GCP Ctr, Inst Drug Clin Trials, Chengdu 610041, Peoples R China; [Jia, Shiling; Huang, Biao] Covance Pharmaceut Res & Dev Co Ltd, Shanghai 200000, Peoples R China; [Zhang, Quan] Suzhou Yabao Pharmaceut R&D Co Ltd, Suzhou, Peoples R China
推荐引用方式 GB/T 7714	Wang, Zhenlei,Jia, Shiling,Zhang, Quan,et al. LC-MS/MS assay for the determination of tat-K13, a novel interfering peptide for the treatment of ischemic stroke, in human plasma and its application to a pharmacokinetics study[J],2021,35(7).
APA	Wang, Zhenlei,Jia, Shiling,Zhang, Quan,Wang, Yongsheng,Huang, Biao,&Zheng, Li.(2021).LC-MS/MS assay for the determination of tat-K13, a novel interfering peptide for the treatment of ischemic stroke, in human plasma and its application to a pharmacokinetics study.BIOMEDICAL CHROMATOGRAPHY,35(7).
MLA	Wang, Zhenlei,et al."LC-MS/MS assay for the determination of tat-K13, a novel interfering peptide for the treatment of ischemic stroke, in human plasma and its application to a pharmacokinetics study".BIOMEDICAL CHROMATOGRAPHY 35.7(2021).